Advancing RAS/RASopathy therapies: An NCI‐sponsored intramural and extramural collaboration for the study of RASopathies

RASopathies caused by germline pathogenic variants in genes that encode RAS pathway proteins. These disorders include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), cardiofaciocutaneous syndrome (CFC), and Costello syndrome (CS), and others. RASopathies are characterized by heterogenous manifestations, including congenital heart disease, failure to thrive, and increased risk of cancers. Previous work led by the NCI Pediatric Oncology Branch has altered the natural course of one of the key manifestations of the RASopathy NF1. Through the conduct of a longitudinal cohort study and early phase clinical trials, the MEK inhibitor selumetinib was identified as the first active therapy for the NF1‐related peripheral nerve sheath tumors called plexiform neurofibromas (PNs). As a result, selumetinib was granted breakthrough therapy designation by the FDA for the treatment of PN. Other RASopathy manifestations may also benefit from RAS targeted therapies. The overall goal of Advancing RAS/RASopathy Therapies (ART), a new NCI initiative, is to develop effective therapies and prevention strategies for the clinical manifestations of the non‐NF1 RASopathies and for tumors characterized by somatic RAS mutations. This report reflects discussions from a February 2019 initiation meeting for this project, which had broad international collaboration from basic and clinical researchers and patient advocates.

[1]  Carol L. Williams,et al.  Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer , 2019, Nature Genetics.

[2]  Clint L. Miller,et al.  iPSC-Derived Cardiomyocytes Reveal Aberrant ERK5 and MEK1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome. , 2019, Circulation.

[3]  H. Hakonarson,et al.  ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor , 2019, Nature Medicine.

[4]  B. Gelb,et al.  Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition. , 2019, Journal of the American College of Cardiology.

[5]  Samantha Dale Strasser,et al.  Tissue-Specific Oncogenic Activity of KRASA146T. , 2019, Cancer discovery.

[6]  Julie C. Sapp,et al.  Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. , 2019, American journal of human genetics.

[7]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[8]  E. Radaelli,et al.  Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination , 2018, Science.

[9]  P. Rodriguez-Viciana,et al.  MRAS: A Close but Understudied Member of the RAS Family. , 2018, Cold Spring Harbor perspectives in medicine.

[10]  P. Crespo,et al.  RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges. , 2018, Current opinion in cell biology.

[11]  F. McCormick,et al.  SHOC2–MRAS–PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis , 2018, Proceedings of the National Academy of Sciences.

[12]  D. Zwijnenburg,et al.  RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. , 2018, Cancer research.

[13]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[14]  M. Loh,et al.  Mutation-Specific Signaling Profiles and Kinase Inhibitor Sensitivities of Juvenile Myelomonocytic Leukemia Revealed by Induced Pluripotent Stem Cells , 2018, Leukemia.

[15]  P. Siegel,et al.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations , 2018, Oncogene.

[16]  J. Charron,et al.  Mek1Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome , 2018, Disease Models & Mechanisms.

[17]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[18]  Manish R. Patel,et al.  First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.

[19]  Y. Matsubara,et al.  Mice with an Oncogenic HRAS Mutation are Resistant to High-Fat Diet-Induced Obesity and Exhibit Impaired Hepatic Energy Homeostasis , 2017, EBioMedicine.

[20]  C. Counter,et al.  Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. , 2017, Cancer research.

[21]  J. Teer,et al.  The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation , 2017, Scientific Reports.

[22]  S. Pfister,et al.  Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk , 2017, Clinical Cancer Research.

[23]  B. Schwartz,et al.  In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy , 2017, PloS one.

[24]  M. Ahmadian,et al.  Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy , 2017, PLoS genetics.

[25]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[26]  G. Tomlinson,et al.  Alternative designs for clinical trials in rare diseases , 2016, American journal of medical genetics. Part C, Seminars in medical genetics.

[27]  K. Rauen,et al.  Pathogenetics of the RASopathies. , 2016, Human molecular genetics.

[28]  Karlyne M. Reilly,et al.  The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway , 2016, American journal of medical genetics. Part A.

[29]  K. Rauen,et al.  Expansion of the RASopathies , 2016, Current Genetic Medicine Reports.

[30]  Narasimhan P. Agaram,et al.  Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma , 2016, The American journal of surgical pathology.

[31]  F. McCormick,et al.  The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation , 2016, Proceedings of the National Academy of Sciences.

[32]  Eun Ryoung Jang,et al.  The function of Shoc2: A scaffold and beyond , 2016, Communicative & integrative biology.

[33]  I. Mihalek,et al.  Mutations in RIT1 cause Noonan syndrome – additional functional evidence and expanding the clinical phenotype , 2016, Clinical genetics.

[34]  Ophir D Klein,et al.  Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome , 2016, The Journal of Neuroscience.

[35]  R. Morita,et al.  Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1*♦ , 2015, The Journal of Biological Chemistry.

[36]  H. Cavé,et al.  Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia. , 2015, Cell reports.

[37]  R. Dunn,et al.  Preclinical assessments of the MEK inhibitor PD‐0325901 in a mouse model of neurofibromatosis type 1 , 2015, Pediatric blood & cancer.

[38]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[39]  S. Shvartsman,et al.  Erratum: RASopathies: unraveling mechanisms with animal models (DMM Disease Models and Mechanisms 8 (769-782)) , 2015 .

[40]  Alcino J. Silva,et al.  The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach , 2015, American journal of medical genetics. Part A.

[41]  C. Der,et al.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? , 2015, Clinical Cancer Research.

[42]  M. Greene,et al.  Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes , 2015, British Journal of Cancer.

[43]  Manuel Desco,et al.  K-RasV14I recapitulates Noonan syndrome in mice , 2014, Proceedings of the National Academy of Sciences.

[44]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[45]  Xuan Zhuang,et al.  Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. , 2014, Current cancer drug targets.

[46]  M. Loh,et al.  Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis , 2014, Human molecular genetics.

[47]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[48]  C. Eckert,et al.  Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. , 2013, Blood.

[49]  Anton J. Enright,et al.  The zebrafish reference genome sequence and its relationship to the human genome , 2013, Nature.

[50]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[51]  D. Morrison,et al.  Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. , 2013, Molecular cell.

[52]  A. Burlingame,et al.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. , 2012, Genes & development.

[53]  N. Duesbery,et al.  MEK genomics in development and disease , 2012, Briefings in functional genomics.

[54]  P. Rosenberg,et al.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[55]  S. Nadaf,et al.  Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[56]  B. Neel,et al.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. , 2011, The Journal of clinical investigation.

[57]  B. Neel,et al.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. , 2011, The Journal of clinical investigation.

[58]  S. Colan,et al.  Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: A Ras/MAPK pathway syndrome , 2011, American journal of medical genetics. Part A.

[59]  M. Loh,et al.  Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia , 2010, Nature Genetics.

[60]  C. Ottmann,et al.  Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.

[61]  C. Der,et al.  Ras history , 2010, Small GTPases.

[62]  Alcino J. Silva,et al.  Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back , 2010, American journal of medical genetics. Part A.

[63]  Michael J Ackerman,et al.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.

[64]  A. Tsygankov,et al.  The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.

[65]  Pablo Rodriguez-Viciana,et al.  A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. , 2006, Molecular cell.

[66]  L. Pick,et al.  Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. , 2006, Human molecular genetics.

[67]  J. Mulliken,et al.  RASA1: variable phenotype with capillary and arteriovenous malformations. , 2005, Current opinion in genetics & development.

[68]  K. Gripp,et al.  Elevated catecholamine metabolites in patients with Costello syndrome , 2004, American journal of medical genetics. Part A.

[69]  C. Der,et al.  Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.

[70]  E. Zackai,et al.  Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. , 2002, American journal of medical genetics.

[71]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[72]  S. Shvartsman,et al.  RASopathies: unraveling mechanisms with animal models , 2015, Disease Models & Mechanisms.

[73]  Joseph P. Near,et al.  How to cite this article , 2011 .

[74]  K. Kawakami,et al.  Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells , 2009, Disease Models & Mechanisms.